Keratin 6A mRNA (KRT6A mRNA)

Mutant Keratin 6A (KRT6A) mRNA is a specific therapeutic target for the treatment of Pachyonychia Congenita (PC), a rare autosomal dominant skin disorder characterized by severe palmoplantar keratoderma and nail dystrophy (Smith et al., 2005, J Invest Dermatol). The KRT6A gene encodes a type II cytokeratin that is essential for the mechanical integrity of epithelial cells in high-stress areas like the palms and soles (UniProt P02538). Mutations in this gene, such as the N171K missense mutation, result in defective keratin proteins that disrupt the assembly of intermediate filaments, leading to cell fragility and hyperkeratosis (Leachman et al., 2010, Nat Med). Therapeutic intervention focuses on the use of small interfering RNAs (siRNAs) to achieve allele-specific silencing, which selectively degrades the mutant mRNA transcript to prevent the production of the toxic mutant protein. This approach aims to reduce the dominant-negative effect of the mutation and allow the wild-type protein to maintain normal cellular structure. The drug candidate TD101 was the first siRNA to be tested in a human clinical trial for this target, demonstrating the feasibility of mutation-specific RNA interference in skin tissue (Leachman et al., 2010, Nat Med). Despite its potential, challenges remain regarding the delivery of these nucleic acid therapies to the skin and ensuring high specificity to avoid silencing the healthy wild-type allele (NIH GARD).

Other names

Keratin, type II cytoskeletal 6A mRNAK6A mRNACytokeratin-6A mRNAKRT6A mutant transcriptCK6A mRNA

Allele-specific RNA interference (RNAi) leading to the degradation of mutant mRNA transcripts while sparing wild-type mRNA.